Trevor J. Resnick, MD

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

The panel discusses future gene therapies in development for Dravet syndrome.

Elaine Wirrell, MD, reviews the transition of care into adulthood of patients with Dravet syndrome and how this transition can affect the patient, caregiver, and care provider.

The panel discusses the impact on the family, siblings, or caregivers of patients with Dravet syndrome.

Elaine Wirrell, MD, provides background on fenfluramine, results from 2 clinical trials, and compares it to other treatment therapies.

Elizabeth Thiele, MD, PhD, reviews cannabidiol oral solution as treatment of seizures associated with Dravet syndrome and the safety profile and dosing associated with it.

Experts in the field discuss second- and third-line treatment options for Dravet syndrome such as stiripentol and vagal nerve stimulation and the effects they’ve seen on patients.

A panel discussion on the North American Consensus statement on treating Dravet syndrome and the approved therapies like clobazam, ketogenic diets, and other first- and second-line therapies.

A discussion on having conversations with the parents of patients with Dravet syndrome with regards to adjustments to therapy and managing their expectations.

A panel of experts discuss treatment goals for patients with Dravet syndrome and how to convey the variability of treatment to the parents of these patients.

Trevor J. Resnick, MD, and Elaine Wirrell, MD, explain why the early diagnosis of Dravet syndrome is important, which patient profiles should be noted for ordering genetic testing, and what to do with those results.  

Elizabeth Thiele, MD, PhD, and Elaine Wirrell, MD, provide an overview of Dravet syndrome and the seizure triggers in pediatric patients.